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collected nine times and oral tissues (tongue, gingiva, submandibular 
lymph node, parotid gland, submandihular gland, mandible) samples 
were collected nine times. The transfer concentration of S-1090 was 
determined by the paper disc method of bioassay using Prm'den- 
cia stuartii (IF0 12930) as the test bacterium and pharmcokinetic 
analysis was carried out. 
Results: Laboratory findings of serum samples were as follows: 
Tmax (1.95 h), Cmax (11.22 pg/ml), AUC (82.52 ,ugh/&) and 
those of tissue samples included the following: Tmax (2.64-4.35 h), 
Cmax (1.62-3.56 pg/g), AUC (22.81-42.72 pgh/g). 
Conclusion: The transfer levels of S-1090 were significantly high 
in the oral tissues including parotid gland and gingiva. 
I P395 I Pharmacodynamic Evaluation of New 
Glycopeptides Using In Viro Models of 
Infection against Methicillin-Resistant 
Staphylococcus aureus (MRSA) 
R.-C. Mercier, M.L. Rybak. The Anti-Infective Research LzboratoT, 
Wayne State University and Detroit Receiving Hospital, Detroit, MI, 
U S A  
Objectives: LY333328 (LY28) and LY191145 (LY45) are two in- 
vestigational glycopeptides which have been shown to have good 
activity against resistant strains of Staphylococcus aureus. We compared 
the activity of LY28, LY45 and vancomycin (V) against one clinical 
strain of MRSA. 
Methods: Three Merent in vim models were used a simulated 
endocardial vegetation (SEV) model, an abscess model (AM) and a 
bacteremic model (BM). A starting inocdum of -lo9 CFU/g was 
used for the SEV model and inocula of--1O6 CFU/rnl were used for 
the AM and BM. The LY compounds were tested in the presence 
or abscence of albumin (Alb, 4 g/dL). Bacterial densities at 48 or 72 
h were compared between regimens. 
Results: MICs/MBCs of the MRSA were LY28: 1/2, LY45: 
0.125/0.25 and V 0.5/1 pg/ml. 
Aloglo CFU/ml or g @ 72 h 
SEV Model Abscess Model Bicteremic model 
A loglo C N / d  @ 48 h 
Regmcn Peakconc. Alh No Alh Peakconc. No Alb Peakconc. Alb No Alb 
( W L )  ( m g 4  (mgW 
LY28 12 +1.4 8 +3.3 40 -3.8 
LY45 12 -0.3 8 -0.9 40 -4.0 
V 30 -2.0 30 -4.1 30 +3.2 
Growrh Connol +0.9 +3.2 +2.8 
30 +1.5 40 -0.7 
30 -0.8 40 -3.6 
Conclusions: In the SEV model, no killing was observed with 
LY28; LY45 and V were sipficandy better than LY28. Sipficant 
binding of the LY compounds to the membrane may occur in the 
AM which could explain the decrease in activity. Structure-activity 
relationship may also be responsible for the Werence between the 
three glycopeptides. 
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lp3961 The in vitm Activity of Trovafloxacine, 
Ciprofloxacine and lmipenem against Clinical 
Isolates from the Intensive Care Units in Central 
Europe 
D. Dzierianowska , J. Patzer 
Memorial Health Institute, Wanatv, Poland, 'Regional Institute .f 
Hygiene, Ostrava, Czech Republic 
Objective: to compare the in-v+ro activity oftrovdoxacine (TFX), 
a new naphthyridone derivative of fluoroquinolone, with that of 
ciprofloxacin (CIP) and imipenem (IPM) against chical isolates 
f h m  the Intensive Care Unit. 
Materials and Methods: The kesh clinical consecutive isolates 
(n = 200) were obtained f h m  patients hospitalized in 1996. The 
Minimal Inhibitory Concentration (MIC) of TFX, CIP and IPM 
was determined by E-test. 
Results: TFX demonstrated greater activity against Sraphylococ- 
cus aureus (MIC90 2 mg/l) and Stapphylococcuc epidermidis 4 
mg/l) in comparison to CIP (MIC90 >32 mg/ml). TXF, CIP and 
IPM were characterized by the MIC9o < = 1 mg/l against all tested 
Gram-negative bacteria, with the exception of Stenotrophomonac mal- 
tophilia. TFX and CIP demonstrated identical activity against Meb- 
siella pneumoniae (MI& 0.75 mg/l) and nearly identical against En- 
terobacter cloacae (MIC90 0.04 mg/l or 0.032 mg/l). CIP was more 
active than TFX against Escherichia mli (MI& 0.23 mgA and 0.38 
mg/l, respectively). Pseudomonas aewginosa and Acinetobacter spp. had 
MIC9o >32 mg/l  for both TFX and CIP. 
Conclusion: TFX was the most active among tested antibiotics 
against clinical isolates of Staphylococcus aureus and Staphylococcus 
epidermidis. It had good activity against all tested isolates of Enter- 
obacteriaceae and 50% of l? aeruginosa. 
E. Chmelarova '. ' Children's 
Activity of Trovafloxacin Compared to 7 Other 
Agents Against 458 Gram-negative 
Nonfermenters 
M.A. Visalli I ,  M.R. Jacobs ', EC. Appelbaum I .  'Hershey Medical 
Center, Hershey, PA, U S A ,  ' C u e  Western Reserve University, 
Cleveland, OH, U S A  
Objectives: To test activity of trodoxacin compared to 
other quinolone and non-quinolone agents against Gram-negative 
non-fermenters. 
Methods: Agar dilution was used to test susceptibility of 
458 Gram-negative non-fermenters to mdoxac in ,  ciprofloxacin, 
ofloxacin, levofloxacin, spadoxacin, clindoxacin, ceftazidime, 
imipenem. 
Results: MIC~o/9os (pg/ml) are given in the table below. 
Conclusions: Trodoxacin yielded low MIC9os (14.0 pg/ml) 
against all common species except B. repacia, Alcaligenes and some 
acinetobacters. 
R ~1mx (89) 
EJuodpuf (13) 
B. qm (49) 
S mdto (82) 
Annets spp (52) 
C. m m q  (10) 
AU (458) 
A h l v  SPP (67) 
OW2.0 
1.0/8.0 
8.0/32.0 
1.0/2.0 
0.06/16.0 
16.0164.0 
1.0/4.0 
1/16 
0.25/4.0 
0.25/4.0 
8.0/32.0 
4.0A6.0 
0.5b256.0 
4.0l32.0 
2.0/8.0 
2/16 
2.0/4.0 
2.0116.0 
16.0/64.0 
4.0/8.0 
0.5/32.0 
8.0/32.0 
4.014.0 
2/32 
1.0/2.0 
1.0/8.0 
4.0/32.0 
1.0/2.0 
0.06/16.0 
4.0/32.0 
OW4.0 
1/16 
1.012.0 
1.0/8.0 
8.0/16.0 
2.0/4.0 
0.5/32.0 
4.0/32.0 
2.0/2.0 
1/16 
0.25/0.5 
0.25/2.0 
2.0/8.0 
0.5/2.0 
0.125/8.0 
0.5/8.0 
1.0/4.0 
OW4 
4.0/64.0 
4.0/64.0 
8.0/32.0 
64.01256.0 
8.0/64.0 
8.0/64.0 
128.0/>256.0 
8/128 
2.0 / 3 2.0 
2.0/256.0 
16.0/256.0 
256.0/256.0 
0.25/0.5 
1.0/8.0 
8.0/64.0 
2/256 
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I P398 I Activiiy of Tmvafloxacin f Ceftazidime, 
lmipenem and Amikacin Against Gram-negative 
Non-fetmenters 
M. Visalli I ,  S. Bajaksouzian ', M. Jacobs ', l? Appelbaum ' .  
'Hershey Med. Ctr., Hershey, PA, USA, 'Case West. Res. Univ., 
Cleveland, OH, U S A  
Objectives: To test activity of trovafloxacin, alone and in combi- 
nation with other combinations, against a range of gram-negative 
non-fermenten. 
Methods: We used checkerboard titration to test activity of 
trodoxacin f ceftazidime, imipenem and amikacin against 286 
non-fermenters. 
Results: MIC9os (gg/ml) of trodoxacin, ceftazidime, amikacin 
and imipenern were: I! aenrginosa: 1, >64, 16, 24;  I! j u o -  
rescens/putida: 8, >64, >16, >4; S. maltophilia: 4, ~ 6 4 ,  >16, >4; 
B. cepacia: 32, >64, >16, >4; Acinetobacter: 8, >64, >16, 1.  Syn- 
ergy testing showed FIC indices as follows: 
P r n f ~ n ( 6 0 ) ~  17d 43 0 14 46 0 5 55 0 
PJuo/pufr(ll) 5 6 0 4 7 0 3 8 0 
S molfophd(36) 32 4 0 1 35 0 4 32 0 
B c r p m d  (32) 5 27 0 2 30 0 1 31 0 
Anmfohz (35) 7 28 0 6 29 0 6 29 0 
Ablzpcs (47) 6 41 0 5 42 0 10 37 0 
FLN/Ch1y5(22) 5 17 0 3 19 0 3 19 0 
'Synergstic; bAdditive/mndiffcSrent; CAnragonirac; dNo. scram tested 
Synergy was also tested by time-kill in 20 strains.  Synergy ( 2 2  log 
&/ml drop at 24 h compared to the more active of the 2 drugs) was 
seen for most combinations with the exception of trova + imipenem 
(S. maltophilia). Synergy testing by time-kill was more ducriminatory 
than by checkerboard. 
Conclusions: Combination therapy with trodoxacin and other 
agents may be useful in treatment of selected non-fermenter infec- 
tions. 
The Efficacy and Safety of Tmvafloxacin in the 
Treatment of Acute Bacterial Sinusitis 
R. Fiddes ', A. Sydor ', I? Johnson ', L. Arce ', S. Pancorbo for 
the Finnish Trodoxacin Sinusitis Study Group. 'Southern California 
Research Institute, Whittier, CA, USA, 2Albennarle Ent. Associates Ltd, 
Charlottesville, VA, USA, 'Ear, Nose and Throat Consultantc of 
Winchester, Winchester, VA, USA, 4Hospital Mexico, San Jose, Costa 
Rica, USA,  5pf;zer Central Research, Groton, C?; USA 
Objective: To study the efficacy and safety of 200 mg oral 
trovafloxacin, a novel fluoroquinolone, for the treatment of acute 
sinusitis. 
Methods: This was an open-label, non-comparative, multicenter 
trial. Patients were treated once daily for 10 days. Diagnosis of acute 
sinusitis was based on clinical assessment of signs and symptoms, and 
confirmed by sinus radiology. Au subjects underwent transantral as- 
piration of the sinus for culture determinations at baseline. Patients 
were monitored at days 4, 11 (end of treatment), and 24 (end of 
study), and the clinical response was categorized as cured, improved, 
or failed. Responses categorized as cured or improved were com- 
bined and classified as clinical success. Au patients had sinus antral 
taps at baseline to obtain specimens for bacteriology. Safety was de- 
termined by monitoring adverse events. 
Results: The most common isolated pathogens were S. pneumo- 
niae, H. inauenzae, S. aureus and M. catanhalis. At the end of study, 
eradication occurred in 96% of patients with baseline S. pneumoniae, 
96% with H. in$uenzae, 100% with S. nureus, and 90% with M .  
catanhalic. No pathogen showed resistance to trova5oxacin. At the 
end of treatment, 91% of subjects were considered clinical treatment 
successes. The most commonly reported treatment-related adverse 
events were dizzmess/lightheadedness, nausea, vomiting, headache, 
and diarrhea. 
Conclusion: Results indicated that trovafloxacin is well tolerated 
and effective. 
I P400 I Comparative In Vim Activii of DU-6859a (DU), 
Tmvafloxacin (TR), Levofloxacin (LE) and 
Sparfloxacin (SP) against Entemcoccus feecalis 
Clinical Isolates 
Ed. Giamarellos-Bourboulis, l? Grecka, A. Mandaraka, 
H. Giamarellou. 1'' Dept. Prop. Med., Athens Medical School, Athens, 
Greece 
Objectives: To compare the in vitm activity of the four newer 
fluoroquinolones DU, TR, LE and SP on E.faecalis. 
Methods: 78 isolates h r n  8 Merent hospitals of the Athens 
b d e u e  were tested. MICs were determined by a microdilution 
technique at a 0.05 ml final volume with a 5 x lo5 &/ml overnight 
inoculum, and MBCs by plating the content of all clear wells (99.9% 
of killing) onto blood-agar plates. 
Results: At a 2 pg/ml breakpoint, results were as follows 
FktngcofMICr MIC50 MICw MBCso MBCgo %inhibited 
264 8 >64 5 7 7  
z64 4 7 3  TR 5003->64 1 
LE ~ 0 0 % > 6 4  8 ~ 6 4  8 >64 359 
264 16 >64 21 8 SP joo3-264 8 
DU 5003->64 2 
32 1 
From 10 isolates resistant to both ampicillin and amoxyciuln + 
clavulanate, 60, 50, 20 and 10% were inhibited by DU, TR, LE and 
SP respectively, and h m  15 highly resistant to both streptomycin 
and gentamicin 26.7, 46.7, 13.3 and 6.7% by DU, TR, LE and SP 
respectively. No glycopeptide resistance was found. 
Conclusions: DU and T R  are equally active and superior than 
LE and SP on E .  jzecalis and also promising new agents against 
cross-resistant isolates to the classic antibiotics. 
In Vitm Activii and Kinetics of Activity of 
Tmvafloxacin Against Bactemides fragilis 
J.A. Garcia-Rodriguez, I. Trujillano. Department ofMicrobiolw, 
University Hospital Salamanca, Spain 
MICgos, determined by Mueller-Hinton agar dilution using stan- 
dard NCCLS procedures, of 40 B. jagilis st ra ins  were lower 
for trovafloxacin (0.6-8 mg/l) than for cipxufloxacin (4->128 
%A), ofloxacin (2->128 mgA), or spdoxacin (0.5-64 mg/l). 
Trodoxacin (MIC90 0.25 mg/l) was also more active than ce- 
foxitin (MICw 64 mg/l), chloramphenicol (MICS0 4 mgA), clin- 
damycin (MIC90 2 mg/l), and metronidazole, imipenem, or ornida- 
zole (MIc9o all 1 mg/l) against B. j a @ .  MBCs of trovafloxacin, 
determined according to NCCLS procedures using broth microdi- 
lution, were two-fold higher than the MICs. Bactericidal activity 
was confirmed by time-kill assay. A three-log decrease in viability 
was observed within 6-8 h of trodoxacin exposure. Agamt both 
B. j a g &  ATCC 25285 and HUS 1134, trodoxacin displayed a 
post-antibiotic effect: afrer removal of 8 x MIC of trovafloxacin, 
2-4 h elapsed before the bacterial count increased 10-fold. The 
minimum inhibitory antibiotic concentration (i.e. the lowest con- 
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centrahon of trovafloxacin that produced a one log reduction in 
CFU/ml over 5.5 h compared with control) was 0.25 x MIC. 
The study indicates that trovafloxacin possesses superior activity 
to other fluoroquinolones and anti-anaerobic agents, and may be a 
useful alternative agent for the treatment of anaerobic infections. 
Trovafloxacin in Combination with Ceftazidime, 
Meropenem, and Amikacin 
D. Milatovic, C. Wallrauch. Institute ofMedicaa[ Microbiology, 
Immunology and Hygiene, Technical University of Munich, Germany 
A total of 182 c h c a l  isolates (111 Gram-negative and 71 
Gram-positive strains) were tested for susceptibility against 
trovdoxacin, ceh idme ,  meropenem, and amikacin. Synergy was 
assessed by the checkerboard method in whch antibiotic combina- 
tions were tested against 46 strains. The fractional inhibitory concen- 
tration (FIC) of each substance at the point of maximal interaction 
was determined; an FIC index 10.5 signified synergy. Synergy was 
re-examined by time-kdl kinetics on selected strains. 
Trovafloxacin demonstrated very good in vitro activity against 
the species tested. Synergy was observed between trovafloxacin and 
ceftawhe in two and between trovafloxacin and meropenem in 
one out of nine Pseudomonac aeruginosa strains; Results were con- 
firmed by time-kill kmetics. Trovdloxacin and amikacin acted syn- 
ergistically against one strain of Mebsiella spp., but t h i s  was not 
supported by time-kill kinetics. Synergy was observed in 9/22 
(41%) Gram-positive strains. In particular, mvafloxacin and amikacin 
demonstrated synergy against 6/12 isolates of enterococci, including 
trovafloxacin-resistant strains.  No antagonistic interactions were ob- 
served. 
In conclusion, trovafloxacin combined with cehidime or 
meropenem acted synergistically against some strains of R aentgi- 
nosa. However, synergy was most pronounced with trovafloxacin 
and amikacin against enterococci, even in strains resistant to 
trovafloxacin. Furthermore, the combination of trovafloxacin with 
any of the three agents tested does not appear to implicate the risk 
of antagonism, which could negatively afTect therapeutic efficacy 
1p403] In Vitm Testing of Trovafloxacin According to the 
DIN 58940 Guidelines: Evaluation of 
Trovafloxacin Discs and Proposal of Tentative 
DIN Breakpoints 
A.E Schmalreck, I. Kottmann, A. Reiser, U. Ruffer, E. Vanca. 
pfizer/Mack Microbiology R&D Laboratories, 0-89257 IlIertissen, 
Germany 
Trovafloxacin is a novel fluoroquinolone antibacterial agent with 
improved in vitro potency against Gram-positive and anaerobic 
pathogens, and with advantageous pharmacokinetic properties en- 
abling once-daily admintstration. 
359 Gram-negative and 518 Gram-positive clinical isolates (17 
genera, 70 species) including 168 streptococci and 104 methi- 
cillin-resistant staphylococci have been tested by microdilution, agar 
dilution and agar a s i o n  accordmg to the German DIN 58940 
guidelines, and the E-test@ strips according to the recommendations 
of the manufacturer. Trovafloxacin discs were prepared with a load 
of 1, 2, 2.5, 5 and 10 pg, and bio-assayed according to DIN 58940. 
The 5-pg discs demonstrated the most appropriate performance 
and inhibition zone diameters (IZD: mean = 22 mm, std f 12 mm; 
median = 24 mm, extremes 6 mm and 55 mm). The 1- and 2-pg 
&cs produced too small IZDs, the 10-pg disc too large IZDs. The 
regression equation for the 5-pg disc was IZD -2.8 x log2(MIC) + 
47.9, with a correlation coefficient for agar difision/microdilution 
of 0.9363. For the evaluation of prelirmnary IZD breakpoints cor- 
relation analysis, MetzeledDeHaan analysis and Kappa analysis were 
performed. Suggested tentative IZD breakpoints accordmg to the 
German DIN guidelines are for Gram-positive and Gram-negative 
bacteria R 513 mm and S 219 mm, and for S f r e p t o c o w  spp. R 1 1 8  
mm and S 224 mm, when, according to the MIC dmribution and 
pharmacokinetic properties of the drug, DIN MIC breakpoints of S 
- (2 p g / d  and R ?8 K g / d  are assumed. 
I P404 I Comparative In Wtm Activities of Trovafloxacin, 
Ciprofloxacin, Ofloxacin, and Fleroxacin Against 
Gram-Negative Blood Isolates 
H. Seifert. Institute for Medical Microbiology and Hygiene, University o j  
Cologne, Cologne, Germany 
The in vitro activity of trovafloxacin (TROV), a novel fluoro- 
quinolone antibiotic, was compared with that of ciprofloxacin (CIP), 
ofloxacin (OFL), and fleroxacin (FL) against 296 Gram-negative bac- 
terial isolates using the agar dilution method isolates were consecu- 
tively recovered from blood cultures of recently hospitalized patients. 
Test strains included An'netobacter spp. (n = 26), Escherichiu coli (n = 
137), Enterobacter spp. (n = 27), Mebsiella spp. (n = 42), Proteus spp. 
(n = 16), Pseudomom amginosa (n = 28), Serratia spp. (n = 13), 
and Stenotrophornonas rnaltophilia (n = 7). Strains were plated onto 
Mueller-Hinton agar at 5 x 10 CFLJ per spot, and the antibac- 
terial activity was tested at concentrations of O.OS128 mgfl using 
DIN and NCCLS guidelines for interpretation. Results expressed as 
MICsos and MICyos, were as follows: 
mov CIP OFL FL 
M I C ~ O  MICgO MIC5o MtC9O MICw MICw MIC50 MlCgo 
~~ ~ 
Adnctsbmt~rrpp. 50.03 0.12 0.25 0.5 0.5 1 0.5 1 
Enmembacterrpp. 50.03 0.5 50.03 0.12 0.06 1 0 12 1 
Klebsieliaspp. 0.12 0.5 ~0.03 0.12 0.12 0.5 0.12 0.5 
Pmtw rpp. 0.25 0.5 <0.03 2 0.12 4 0.25 2 
I?amrgtms'7 1 2 0.25 1 2 4 1 4 
Smarrorpp. 1 16 0.25 8 1 16 1 8 
S. maltophilin 1 2 4 8 2 4 2 4  
Data obtained show the similar activity of TROV and CIP against 
Gram-negative pathogens. TROV was the only Auoroquinolone that 
was consistently active against S. maltophiliu. 
I P405 1 In vitm Antibacterial Activity of a New 
Fluoroquinolone, Levofloxacin, against Hospital 
Isolates: A Multicenter Study 
C.J. Soussy ', M. Cluzel', M.C. Ploy ', M.D. Kitzis ', C. Morel ', 
A. Bryskier 6, P. Courvalin '. ' CHU Henri Mondor, Crbtel, France, 
'CHU Clermont-Ferrand, Paris, France, CHU Limoges, Paris, France, 
4H~pital  Saint-Joseph, Paris, France, 'CH74 Caen, France, 
6Roussel- Ucld Romainville, France, 'Institut Pasteur, Paris, France 
Objectives: To study the activity of a new fluoroquinolone (FLQ), 
levofloxacin (LVFX), the L-isomer of ofloxacin ( O R )  against hos- 
pital isolates. 
Methods: Minimal inhibitory concentrations (MICs) of LVFX 
were determined by agar dilution for 2053 bacterial strains: antibi- 
ograms by agar a s i o n  were performed with 5 p g  disks to calculate 
the breakpoints for sensitivity testing. Quality control was performed 
at the Institut Pasteur. 
Results: The activity of LVFX against nalidixic acid-susceptible 
(NAL-S) Enterobactniaceae (n = 668) was higher (MIC 50 and 90: 
0.06-0.12 pg/ml) than for OD(: as for other FLQs, this activity was 
reduced against NAL-intermediate (I) and -resistant (R) strains (n 
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= 260) (1-8). MICs against Ps. amginosa (n = 104) were between 
0.12 and 128 (4-64). LVFX had a good activity against NAL-S 
A .  baumannii (n = 12) (0.06-0.25), but this activity was reduced 
against NAL-R strains (n = 80) (1-32). H .  inzuenzae (n = 70), H .  
parainjuenrae (n = 47) and B. catarrhalis (n = 64) were inhibited 
by low concentrations (0.016-0.03; 0.03-0.12; 0.03-0.12). C. per- 
jmgens (n = 23) (0.25-1) was more susceptible than B. @agilis (n 
= 60) (0.5-4). LVFX showed superior activity to OFX against me- 
thicillin-susceptible staphylococci (n = 107) (0.03-0.5); the resistant 
strains (2-32) were usually methicdh resistant LVFX was less ef- 
fective against enterococci (n = 104) (1-32), but streptococci (n = 
192) and pneumococci (n = 129), including 58 penich-resistant 
strains, were inhibited by low concentrations (0.5-2). According to 
the regression curve, zone diameters were usually 21-23, 19-20 and 
17-18 mm for MICs of 1 , 2  and 4 pg/ml. 
Conclusions: This study, performed on a large number of strains, 
confirms the superior antibacterial activity of LWX, compared to 
OFX, especially against pathogens isolated from respiratory tract in- 
fections. 
I P406 I Susceptibility to Levofloxacin of Clinical Isolates 
from Intensive Care and Haematology/Oncology 
Patients in Swiiedand: A Multicentre Study 
H.H. Siegrist, M.-C. Nepa, A. Jacquet. Instifut Neuchdtelois de 
Microbiologie, La Cham-de-Fonds, Switzerland 
Objectives: To study the susceptibility of clinical isolates from 
ICU (59%), oncology wards (7%) and other units with haemato- 
logca/oncological patients (34%) prospectively collected from June 
1995 to March 1996 to levofloxacin (LEV), a new quinolone with 
extended activity on gram-positive bacteria, and other antibiotics in 
11 Swiss clinical microbiology laboratories using the NCCLS disk 
*ion techmque. LEV breakpoints used were the manufacturer's. 
A total of 310 gram-positive and 580 gram-negative strains from res- 
piratory tract (36%), skidwound (12%), blood (16%), urine (17%) 
and other sources (19%) were adysed. 
Results: The susceptibility to LEV of the 853 (96%) most fie- 
quent isolates to a selection of antimicrobial agents was for Entemcoc- 
fus spp. (38 strains) 100%; S. aureus (95 of which 2% MRSA) 94% 
CNS (85) 65% S. agalacfiae (13) 100%; S. pneumoniae (65) 100%; 
Acinetobacfer spp. (11) 100%; C. diwrsus (6) 100% C. jeundii (17) 
100% Enterobacter spp. (75) 99% E.  coli (111) 97% K. oxytoco (39) 
100%; K. pneumoniae (45) 98% M .  morganii (16) 100% l? mirabilis 
(20) 100%; P vulgaris (23) 100% l? amginosa (124) 87% Smatia spp. 
(19) 100%; S. maltophilia (10) 100% and H. influenme (41) 100%. 
Conclusion: LEV is a new quinolone with high in vim activity 
against the most common clinical isolates in Switzerland. Its achvity 
against Enkrococcus spp. and Streptococcus pneumoniae is particularly re- 
markable. It htinguishes this new molecule from other Comparable 
and already aMilable quinolones. 
1 P407 I In vitm Susceptibility of Streptococcus 
pneumoniae Isolates to Levofloxacin: Results 
from a Clinical Study 
B.I. Davies, EPV. Maesen, W De Zickenhuis. Heerlen, The 
Netherlands 
Objectives: To compare levofloxacin with cefuroxime axed in a 
mndomised, double-blind study in 140 patients with acute purulent 
exacerbations of chronic bronchitis. 
Methods. Sputum cultures were monitored pre-treatment and 
1, 7 and 21 days after the end of treatment. Susceptibility of S. 
pneumoniae isolates was tested by agar ddution in Columbia blood 
agar and by disk &sion (5 pg lwofloxacin &). All tests were 
incubated overnight at 37OC in 6% COz. 
Results: AU 39 pre-treatment isolates yielded lwofloxacin MIO 
between 0.25 and 2 mgA (geometric mean 0.95). and the 32 
post-treatment strains were fairly M a r  (G.M. value 1.11 mg/l). 
76 strains from our culture collection yielded comparable results, 
although some MICs of 0.5 (8 times) or 4 mgA (4 times) were 
recorded. MICso and MI% values were 1 and 2 mgA, mpec- 
tively. Disk-diffusion tests showed zone of inhibition diameters 
pre-treatment to average 24.4 ryn (range 18-38), post-treatment 
isolates yielding zones averaging 24.5 mm (range 2040). AU except 
one of the strains studied were susceptible to penicillin with MIC 
values 50.03 mgA. One isolate showed a p e n i d h  MIC of 0.5 
mgA, but it was fully susceptible to levofloxacin. 
Conclusions: It is clear that rapid resistance to levofloxacin does 
not emerge during therapy with this drug, and that natural resistance 
in pneumococci is rare. 
[p4081 In vitm Activity of Levofloxacin, a New 
Fluoroquinolone. Evaluation on H. influenzae 
and B. catahalis 
M.D. Kitzis, EW Goldstein, M. Miegi, J.E Acar. Fondation H6pital 
Saint Joseph, Paris, France 
Objectives: The in uitro activity of levofloxacin (LVFX) was studied 
on 10 B-lactamase negative (B- )  and 93 B-lactamase positive (B+) 
B. catanhalis (Bc) and on 65 p- and 35 p+ H .  infienzae (Hi). 
Methods: The MICs of LVFX were determined by agar dilu- 
tion in Mueller-Hinton agar (+HTM for Hi; +5% horse blood for 
Bc) and were compared to those of ofloxacin (OFX), ciprofloxacin 
Results The MIC (pglml) range and (90%) were as follows: 
(CPFX), ~parA0xacin (SPFX) and d-ofl-cin. 
LVFX OD( CPFX SPFX 
Hi 0.0039-0.03 0.0078-0.06 0.0039-0.03 0 0019-0.03 
(0.03) (0.06) (0.03) (0.03) 
(0.06) (0.125) (0.06) (0.03) 
Br 0.03-0.25 0.06-0.25 0.0078-0.125 0.007WJ.M 
These fluoroquinolones showed similar activity against isolates of 
Hi and Bc irrespective of B-lactamase production. LVDC (MIC50190: 
0.06 pg/ml) was 64 times more active than d-ofloxacin (MIC50190: 
4 hg/ml) and twice as active as OFX (MIC50/w): 0.125 ,ug/ml). 
an MIC50190 of 0.015 h g / d  against Bc whatexr the resistance phe- 
notype of the isolates. 99 of 103 Bc isolates were inhibited by 0.06 
,ug/ml of LVFX. Agamst Hi LVFX was twice as active as OFX 
(MIC90 values 0.03 pg/ml versus 0.06 pg/ml) and showed the same 
range of activity as CPFX. 
Conclusions: Our results suggest that LVFX has potential for 
treating respiratory tract infections caused by Hi and &. 
CPFX showed MIC50/90 of 0.03/0.06 pg/ml and SPFX showed 
LP409 I Italian Survey on Levofloxacin Susceptibilii in 
Clinical Isolates of Pseudomonas aenrginosa 
Compared to other Antibiotics 
B. Segatore, D. Setacci, M.G. Perilli, N. Franceschini, A. De Santis, 
E Marchetti', G. Amicosante. STBB Dept., University OfL'Aquila, 
Milan, Italy, 'Medical Dept., Hoechst Marion Roussel, Milan, Italy 
Objectives: To survey the susceptibility to levofloxacin, a new in- 
jectable and oral fluoroquinolone, of clinical isolates of I! amginosa 
obtained in Intensive Care Units (ICU) and Haematology/Oncology 
wards compared to other antibiotics. 
New quinolones I 93 
Methods Each of the 12 participating hospitals was requested to 
collect at least 25 consecutive no-copy clinical isolates of r? aenrg- 
inosa h m  selected wards. All s p a i n s  were centralized at our labo- 
ratory for c o n b a t i o n  and sensitivity evaluation. The susceptibil- 
ity to amikacin, imipenem, ceftazidune, ciprofloxacin, ofloxacin and 
levofloxacin was assessed by broth microdilution following NCCLS 
recommendation. Levofloxacin breakpoints were: susceptible 5 2  and 
resistant 28 mg/L. 
Results: A total of 255 strains have been collected at present, 
coming h m  ICU (82%), Oncology (14%) and Haematology (4%). 
The preliminary results showed amikacin to have the best suscepti- 
biIity profile (93%) followed by imipenem (87%), ceftazidune (62%), 
levofloxacin (54%), ofloxacin (34%) and ciprofloxacin (21%). 
Conclusions: The reported data evidenced that levofloxacin in 
liiho activity on I! amginosa in ICU and Haematology/Oncology 
is higher than other fluoroquinolones and can represent a suitable 
choice for therapeutic purposes. 
I P410 I The Efficacy and Safety of Grepafloxacin (GREP) 
400 mg qd or 600 mg qd in the Treatment of 
Acute Bacterial Exacerbations of Chronic 
Bronchitis (ABECB): Comparison with 
Amoxycillin (AMOX) 500 mg tid 
C. Langan', R .  Cranfield', S. Breixh3, R. Petit3. 'Baillieston 
Health Centre, Glasgow, UK, 'Cwmbran, Gwent, UK, 'Otsuka 
America Pharm. Inc. Rockuille, M D ,  US 
Grepafloxacin is a fluoroquinolone with activity against respiratory 
pathogens including penicdin-resistant S. pneumoniae. The elimina- 
tion half-life is -15 hours enabling once-daily dosing. In a ran- 
domized, prospective, double-blind, multicentre study, 656 patients 
between 18 and 80 years with ABECB received 7-10 days of oral 
therapy with GREP 400 mg qd (n = 219), GREP 600 mg qd (n = 
219) or AMOX 500 mg tid (n = 218). Assessments were made at the 
end of treatment (EOT) and 2 weeks after the last dose (F/U). Clin- 
ical responses were expressed as success (cure/improvement) or fail- 
ure (fd/relapse). Microbiological responses were defined as success 
(eradication) or failure (persistence, presumed persistence or relapse). 
The clinically evaluable population comprised 634/656 (95%) pa- 
tients and 542 pathogens were isolated h m  479 patients. The most 
common isolates were H .  infuenzae (41%), S. pneumoniae (23%) and 
M .  catanhalis (19%). All pre-treatment S. pneumoniae were susceptible 
to GREP, but five strains had intermediate susceptibility to AMOX. 
Pathogen eradication was svpficantly greater with GREP at EOT 
and GREP 600 mg at F/U. All treatments were well tolerated; the 
most frequently reported drug-related adverse events in each group 
were nausea, headache and taste perversion, most of which were 
mild or moderate in severity. Ten-day courses of GREP 400 mg or 
600 mg given qd were as effective as AMOX 500 mg tid in the 
treatment of ABECB. 
C h ~ d  Success Microbiological Svcccss 
GREP400 GREP600 AMOX GREP400 GREP600 Ah4OX 
EOT 186/207 194/207 187/203 170/175* 168/171* 174/196 
FIU 165/202 175/206 172/203 144/168 150/164* 162/195 
(90%) (94%) (92%) (97%) (98%) (89%) 
(82%) (85%) (85%) (86%) (92%) (83%) 
I P411 I The Efficacy and Sakty of Single Dose 
Grepafloxacin (GREP) 400 mg in the Treatment 
of Uncomplicated Gonococcal Cervicitis in 
Females: Cornparison with Single Dose Cefixime 
(CFX) 400 mg 
T. M~~czkowski', E. Hook', R. Jones3, W. McCormack4. 'Univ. 
School o fMed . ,  New Orleans LO, USA, 'Univ. Alabama, Birmingham 
A L ,  U S A ,  31ndiana Univ. School Med, IN, U S A ,  4SUNy Health 
Science Center U S A  
Single dose oral treatment of gonococcal cervicitis has advan- 
tages in terms of ease of administration and patient compliance. 
Grepafloxacin is a fluoroquinolone with good in vitro activity against 
Neisseria gononhoeae (MICw = 0.004 pg/mL). In a randomized, 
prospective, open-label, multicenter study, 380 female patients with 
uncomplicated gonococcal cervicitis received single dose o d  ther- 
apy with GREP 400 mg (n = 191) or CFX 400 mg (n = 189). A 
total of 386 pretreatment isolates of N gononhoeae were recovered 
h m  282 patients, 255 of whom were evaluable. A third of those 
(93 of 282) with documented gonococcal cervicitis also had involve- 
ment of the pharynx and/or rectum. All isolates were susceptible to 
GREP and one had reduced susceptibilrty to CFX, 71/386 (18%) 
were penicih-resistant (25 of whch produced beta-lactamase) and 
52/386 (14%) were tetracycline-resistant. All pharyngeal (n = 15) 
and rectal (n = 32) gonococcal infections treated with GREP were 
cured, whereas 5/16 (31%) pharyngeal and 1/38 (3%) rectal in- 
fections failed to respond to CFX. GREP achieved a sigdicantly 
higher clinical response than CFX in evaluable patients (96 versus 
85%, 95% CI 1.1%, 17.8%. *P c 0.05). 
Chmcd succcss Microbiolagc Success 
GREP CFX GREP CFX 
145/147 (9%) 144/149 (95%) 149/150 (96%). 149/153 (85%) 
Both treatments were well tolerated; the most hquently reported 
drug-related adverse events in each p u p  were vaginitis, nausea and 
vomiting, most of whch were mild or moderate in severity. Results 
demonstrate that a single dose of GREP 400 mg was more effective 
than a single dose of CFX 400 mg in the treatment of females with 
uncomplicated gonococcal cervicitis. 
LP412 1 In vitro Activity of Grepafloxacin Against 
important Pathogens that Cause Lower and 
Upper Respiratory Tract Infections 
J. Focht, K. Nosner. B I O S C I E N T I A ,  Instifutefor laboratory medicine 
M o m ,  Germany 
Introduction: There is continued interest in the development of 
new fluoroquinolone antimicrobial agents in order to improve an- 
tibacterial activity, overcome bacterial resistance or improve the 
pharmacokinetics of these agents. Grepafloxacin (OPC1-7116) is 
a new fluoroquinolone with increased activity against gram posi- 
tive respiratory pathogens such as Streptocouus pneumoniae. Clinical 
trials are underway with grepafloxacin for a broad range of indi- 
cations especially respiratory tract infections in a once daily dosage 
regime. 
Objectives: In this report, we studied the antibacterial activity of 
grepafloxacin against more than 1200 s p a i n s  usually responsible for 
respiratory tract infections in general practice in comparison with 
Ciprofloxacin, Amoxicillin, Amoxicillin/Clavulanic acid and Rox- 
ithromycin. 
Method The minimal inhibitory concentrations (MIC) were de- 
termined accordmg to the guidelines of the NCCLS. Antimicro- 
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b d  susceptibility was measured by a microdilution method with 
Mueller Hinton supplemented with Calcium and Magnesium for 
Morarella catanhalis species, with 5% lysed horse blood for Sheptococ- 
cus pneumoniae and with 1% NAD for Haemophilus influenzae. The 
following species were tested S. pneumoniae (250 s t r a i n s ) ,  H .  influen- 
zae (300 strains), H .  parainfluenzae (68 strains), M .  catarrhalis (150 
strains), S. aureus (200 strains), S. pyogenes (105 s t r a i n s ) ,  K .  pneu- 
moniae (70 strains), M .  pneumoniae (50 strains), L. pneumophila (11 
Results: All tested strains were susceptible to Grepdoxacin. The 
MIC90 values of Grepafioxacin ranged h m  0.125 mgA to 0.5 mg/l 
for S. aureus, S. pyogenes, S. pneumoniae, M .  pneumoniae and L. pneu- 
mophila. The MIC9o-values for Ciprofloxacin in these st ra ins  were 
higher, with values ranging between 1 mg/l to 8 mg/l. Agamt 
H .  influenzae and parainfluenzae, M .  catarrhalis and K .  pneumoniae. 
Grepailoxacin was more active than Cefixime, Amoxicillin, Rox- 
ithromycin and the activity was comparable with the activity of 
Cipro5oxacin against this strains. Grepailoxacin showed excellent 
activity against M .  pneumoniae and L. pneumophila. 
Conclusions: The broad spectrum of activity of Grepafioxacin, 
together with its enhanced activity against certain pathogens, such as 
gram-positive cocci compared with the quinolones currently avail- 
able, suggest that this compound will be of use in a wide range of 
clinical conditions especially respiratory tract infections. 
strains). 
(1 In vitro Activii of Enoxacin vs Ciprofloxacin, 
Fleroxacin, Lomefloxacin, Ofloxacin, and 
Pefloxacin against Uropathogens 
K.G. Naber, M. Well, K. Hollauer, D. Kirchbauer, W. Witte. St. 
Elisabeth Hospital, Straubing, Robert Koch Institute, Wernigerode, 
Minimum inhibitory concentrations (MIC) of enoxacin versus 
ciprofloxacin, fleroxacin, lomefloxacin, ofloxacin, and pefloxacin 
were determined against 400 uropathogens cultured h m  the urine 
of urological patients with complicated and/or hospital-acquired uri- 
nary tract infections (UTI) using an agar dilution method. The 
bacterial spectrum consisted of Enterobacteriaceae (34.5%). ente- 
rococci (31.5%), staphylococci (21.2%), and non-fermenting bacte- 
ria (12.8%). Enoxacin inhibited all but one strain (E. cloacae) of 
Enterobacteriaceae up to a MIC of 1 mgA (MIC90 0.25 mg/l). 
As regards the total bacterial spectrum, enoxacin inhibited 54.5%, 
59.5%, 76.0% and 83.8% up to a MIC of 1 mg/l, 2 mg/l, 4 mgA, 
and 8 mgA, respectively. If the same breakpoint of resistance for 
ofloxacin according to DIN 58 940 (NCCLS), i.e. MIC 2 4  mg/l 
(28 %A), is also taken for the other fluoroquinolones, and the 
126 strains of enterococci are excluded, the following resistance rates 
were found ciprofloxacin and enoxacin 15.3% (15.0%), ofloxacin 
17.2% (15.3%), pefloxacin 18.2% (15.3%), fleroxacin 19.3% (15.3%), 
and lomefloxacin 19.7% (17.9%). Accordmg to its in vim activity 
enoxacin can be considered a good alternative fluoroquinolone agent 
for the treatment of complicated UTI. 
I P414 I Susceptibility of Three Leading Respiratory 
Pathogens to Sparfloxacin and Other Antibiotics 
in Germany 
R. Marre M. Kresken for the German SPAR Study Group. 
'Department ofMedical Microbiobgy, University of Ulm, Cumany, 
'Rhdne-Poulenc Rorer, Cologne, Germany 
Objectives: To evaluate the fkquency of antibiotic resistance 
in strains of Sfreptococas pneumoniae (Sp), Haemophiluc influenzae 
(Hi), and MoraxeZla catanhalis (Mc) isolated h m  adult patients 
with community acquired lower respiratory tract infections and 
to assess the in vitro activity of sparfloxacin in comparison to 
ciprofloxacin. 
Methods: During the study period (December 1994 to Decem- 
ber 1995) a total of 254 s t r a i n s  sampled h m  234 patients were 
collected in 7 German laboratories. MICs of 200 strains (105 Sp, 
72 Hi, and 23 Mc) were performed in a central laboratory using 
the broth microdilution method according to the recommendations 
of the NCCLS. Beta-lactamase production was detected by nitro- 
cefin. 
Results One out of the 105 Sp strains (1.0%) was not suscep- 
tible to penicillin (MIC 0.25 mgA). Resistance rates of Sp to ery- 
thromycin (E), cotrimoxazole (SXT) and tetracycline (T) were 6.7%, 
2.9%, and 11.4%. respectively. The rate ofbeta-lactamase producing 
strains was 2.8% for Hi, while that of Mc was 78.3%. One strain of 
Hi was resistant to SXT, and no strain resistant to T. No strains of 
Mc were resistant to E, SXT or T. Sparfloxacin was 4 to 8 times 
more active than ciprofloxacin against Sp (MIGO 0.25 mg/l vs 2 
mgll), Hi (MIC90 0.015 mg/l vs 0.06 mgA) and Mc (MICw 0.015 
mg/l vs 0.06 mgA). All strains were inhibited at a concentration of 
0.5 mg/l of spadoxacin. 
Conclusions: The kequency of antimicrobial resistance in adults 
with community acquired lower respiratory tract infections was low. 
Sparfloxacin was highly active against Sp, Hi and Mc. 
I P415 I Effect of Sub-MICs of Quinolones on Shigelra 
A. Hogtack, E. Karelov6, I. kiknir. Institute o f h e n f i w  and 
Clinical Medicine, Bratislava, Slovakia 
Objectives: To evaluate the outer membrane proteins (OMPs) 
and the hydrophobicity of the cell surface of Shigella dysentm'ae 
1 after treatment with subinhibitory concentrations (sub-MICs) of 
quinolones. 
Methods: Bacterial suspensions exposed to 114 or 1/8 of the 
MICs of the tested antibiotics were incubated (24 h, 37°C) and 
bacterial pellets obtained after their centrlfugation were used for hy- 
drophobicity determination and isolation of OMPs. O m s  were an- 
alyzed by SDS-PAGE. The hydmphobicity was investigated by salt- 
ing-out test (SAT) at which the lowest concentration of (NH4)2S04 
causlng visible bacteria aggregation was determined. 
Results: Ciprofloxacin (MIC = 0.19 pg/ml), ofloxacin (0.78 
,ug/ml), pe5oxacin (3.12 pg/ml) and enoxacin (6.25 pg/ml) at con- 
centrations of 1/4 or 1/8 of the MICs did not Sec t  the profiles of 
the outer membrane proteins of the s h a h  studied. Treated cells ex- 
hibited the same protein bands profile as compared to controls. Also 
hydrophobicity of Shigella dysenteriae 1 was not altered after treatment 
with sub-MICs of quinolones. 
Conclusions: Hydrophobicity and OMPs of Shigella dysenteriae 2 
were not changed after treatment with sub-MICs of quinolones. 
dysenteriae 1 
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(p4161 International, Multi-Center Investigation of 
LB20304, a New Fluoronaphthyridone 
R. Frei ' , A. Hohl ' , V Punter', A. von Graevenik ', C. Knapp ', 
J. Washington ', D. Johnson ', R. Jones '. 'Bacteriology Laboratory, 
University Cliniq Busel, Switzerland, ' Clinical Microbiology Laboratory, 
Institute $Medical Microbiology, Zurich, Switzerland, 3Department of 
Clinical Pathology, The Cleveland Clinic Foundation, Cleveland, OH, 
USA, 4Department $Pathology, University o f  Iowa College o f  Medicine, 
Iowa City, IA, U S A  
Objective: To evaluate the in vitro activity and spectrum of a new 
fluoronaphthyridone, LB20304, compared to six other quinolones 
in four laboratories. 
Methods: A total of 379 strains were tested, using NCCLS ap- 
proved microtiter MIC tesang. 
Results: LB20304 exhibited a spectrum and activity closest to 
that of trodoxacin and chnafloxacin versus Gram-positive cocci, 
but was less active than ciprofloxacin against Enterobacteriaceae and 
Pseudomonas aeruginosa. The rank order of spectra (% lnhibited at 
- <1 mg/l) favored clinafloxacin (92%) > LB20304 = trodoxacin 
(87%) > sparlloxacin (80%). Overall spectrum among the clinically 
adable  drugs favored ciprofloxacin = ofloxacin (80%) > fleroxacin 
(76%). Agamst Sfenohophomonus maltophilia, clinafloxacin demon- 
strated the hghest activity (MIGO, 0.5 mg/l). No sigdicant dif- 
ferences in activity were noted between centers. 
Conclusion: LB20304 appears to possess in vitro potency and 
spectrum characteristics comparable to clinafloxacin, trodoxacin 
and spadoxacin, i.e., other promising new quinolones. 
Does an In Viiro Synergism Between Newer 
Fluoroquinolones and Gentamicin (GM) on 
Enterncoccus faecalis May Exist? A Preliminary 
Report 
E.J. Giamarellos-Bourboulis, H. Sambatakou, Z. Chrysouli, 
H. Giamarellou. 1" Dept. Prop. Med., Athens Med. Srhool, Greece 
Objective: The in vim synergy between two fluoroquinolones, 
DU-6859a (Dv) and trovofloxacin (TR), and GM on E.&ecalis. 
Methods: Nine isolates resistant to both DU and TR (MIC: 8 to 
>64 pg/ml) possessing an MIC to GM >16 p g / d  were exposed 
over time to 2 p g / d  of DU or TR and 10 p g / d  of GM i.e. 
concentrations equal to their mean serum levels. Tubes of a 10 ml 
final volume and a 5 x lo5 cfu/ml overnight inoculum were applied 
and bacterial growth was measured at 0 time, 2, 4, 6 and 24 h of 
growth at 37°C. AU isolates were exposed to DU + GM and seven to 
'IR + GM. A total of 50 killing-curves was performed and synergy 
was defined as any 2 2  loglo decrease of viable cell counts compared 
to the most active single agent. 
Results: Synergy was found for two (22.2%) and 0 isolates at 4 h; 
for two (22.2%) and one (14.3%) at 6 h; and for five (55.6%) and two 
(28.6%) at 24 h by DU and GM and by TR and GM respectively. 
Synergy by DU and GM at 24 h involved two hghly streptomycin 
and gentanicin resistant isolates (MIC >lo00 pg/ml) while two 
ampicillin-resistant isolates dld not express synergy. 
Conclusions: Even though further in vitro observations are nec- 
essary, the combination of DU and GM might be promising for 
multiresistant E. faecalis infections. 
Glycopeptides for enterococci and other 
Gram-positive cocci I 
I P418 1 Vancomycin-Sensitive and Resistant 
Enterococcal Nosocomial Bacteremia in Cancer 
Patients 
S .  Spanik, F! Pichna, J. Trupl, A. Kunova, K. Kralovicova, 
A. Krchnakova, E. Kukuckova, E. Oravcova, A. Demitrovicova, 
I. Krupova, K. Stopkova, S. Grausova, J. Svec, V. Krcmery, Jr., 
F! Pichna. St. Elizabeth Cancer Institute, University o f  Bratislava, 
Postgrad. Med. School, Sfom& Republic, National Cancer Institute, 
University o f  Tmava, Slova& Republic 
A retrospective analysis of 68 episodes of Enterococcal bacteremia 
in 67 cancer patients within 6 years was performed. 60 episodes 
(88.2%) were due to vancomycin-sensitive Enferococrus (E.) faecalis 
and 8 (1 1.7%) due to (vancomycin resistant) E. foecium. Incidence of 
enterococcal bacteremia increased from 1.6 per 1000 admissions in 
1989 to 14.6/1000 a b s i o m  in 1994, however the proportion of 
vancomycin-resistant bacteremia was low and relatively stable despite 
15x increase of vancomycin consumption in 1994 in comparison 
to 1989. Central venous catheter insertion (76.4%), previous ther- 
apy with cephalosporines (54.4%), vancomycin (58.8%), previous 
prophylaxis with quinolones (41.2%), and acute leukemia (39.7%) 
appeared most kquently among bacteremias. More than one half 
of cases of bacteremia were polymicrobial. Comparing both groups, 
there was no difference in clinical course and outcome between 
E. f.ecafis (60 patients) and E.  fecium (8 patients). Previous therapy 
with an aminoglycoside, or breakthrough bacteremia were sigdicant 
more hquently associated vancomycin-resistant E. faecium than with 
vancomycin-sensitive E.fecafis. Mortahty was s d a r  in both groups 
- 12.5% in E.fmcalis and 18.3% in E.fnecium bacteremia respectively. 
[=I National Surveillance Study on Glycopeptide 
Resistant Enterococci (GRE) in Belgium: Report 
of the First Semester of 1996 
B. Gordts ', H. Van Landuyt', M. Ieven', F! Vandamme', 
H. Goossens2 for the GOSPIWGDEPIH Group. 'A.Z. St.Jan, 
Bnqge, Belgium, 'University o f  AnmeT, Belgium 
G m  have become major nosocomial pathogens in the U.S.A., and 
also emerged in Europe. In Belgium, sporadic infections but no 
epidemic with GRE were described before 1996, although asymp- 
tomatic carriers were frequently found. In order to develop an ad- 
equate preventive strategy, we set up a continuous national surveil- 
lance study on GRE from Jan. 1, 1996 on. Suay-four Beban labo- 
ratories agreed to collaborate. During the l th and 2nd trimester of 
96, respect. 30 and 34 laboratories send their local epidemiological 
data firom which we could calculate that the incidence of Entero- 
coccus spp. in chical samples was 2.5%. GRE were reported h m  
15/281,000 samples (0.005%), (0.22% of all enterococci). AU but 1 
patient had been admitted to a hospital. GRE infection occurred in 
1.5/10,000 hospital admissions. Twelve lab's send us 58 enterococci 
presumably resistant to glycopeptides. Only 29 (50%) proved to be 
G m :  5 E.faecalic (17%). 22 E. foecium (76%), 1 E. gallinarum and 1 
E. cusselfivus. The majority of strains demonstrated the mnA geno- 
type (90%) in PCR. One strain was vanB positive, and 2 strains mnC. 
DNA macrorestriction analysis (Smal) showed that 72% of the iso- 
lates were genomically unrelated. Four pairs of strains had identical 
PFGE types. Half of those were recovered €-om one hospital, but the 
epidemiological relation of the other 4 strains remains unclear. The 
preliminary results of this national study demonstrate that G m  in- 
fections are still very rare in Belgium, occur sporadlcally, but mostly 
